These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27081865)

  • 1. Effect of erythropoietin stimulating agents on vascular endothelial growth factor levels in patients with end stage renal disease.
    Saluk JL; Bansal VK; Hoppensteadt DA; Syed DA; Abro S; Fareed J
    Int Angiol; 2017 Apr; 36(2):197-201. PubMed ID: 27081865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.
    Beach LB; Wild M; Ramachandran G; Ikizler HO; Cavanaugh KL
    BMC Nephrol; 2016 Jul; 17(1):86. PubMed ID: 27430294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing anemia management in hospitalized patients with end-stage renal disease.
    Heung M; Mueller BA; Segal JH
    Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Hemoglobin Cycling and Its Clinical Impact on Outcomes in Thai End-Stage Renal Disease Patients Treated with Hemodialysis and Erythropoiesis-Stimulating Agent.
    Thanakitcharu P; Jirajan B
    J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S28-37. PubMed ID: 27266213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.
    Freburger JK; Ellis AR; Wang L; Butler AM; Kshirsagar AV; Winkelmayer WC; Brookhart MA
    Am J Kidney Dis; 2016 Feb; 67(2):271-82. PubMed ID: 26508682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease. Associations with laboratory findings, comorbidities, and medications.
    Erturk I; Yesildal F; Acar R; Ozgurtas T; Saglam K
    Saudi Med J; 2018 Jun; 39(6):586-591. PubMed ID: 29915853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of levels of vascular endothelial growth factor in patients with ESRD and its possible role in cardiovascular morbidity and mortality.
    Thethi I; Bansal V; Khan H; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2012 Sep; 18(5):534-7. PubMed ID: 22311631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors related to the absence of anemia in hemodialysis patients.
    Verdalles U; Abad S; Vega A; Ruiz Caro C; Ampuero J; Jofre R; Lopez-Gomez JM
    Blood Purif; 2011; 32(1):69-74. PubMed ID: 21346339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of metabolic syndrome in patients with end stage renal disease and relevance of biomarkers.
    Saluk J; Bansal V; Hoppensteadt D; Syed D; Abro S; Fareed J
    Int Angiol; 2016 Feb; 35(1):47-56. PubMed ID: 25476033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor in peritoneal dialysis patients.
    Jovanović N; Božinovski SŽ; Krstić S; Obrenović R; Trbojević-Stanković J; Stojimirović B
    Clin Lab; 2014; 60(10):1695-701. PubMed ID: 25651716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients.
    Luo J; Jensen DE; Maroni BJ; Brunelli SM
    Am J Kidney Dis; 2016 Nov; 68(5):763-771. PubMed ID: 27528373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy.
    Brophy DF; Daniel G; Gitlin M; Mayne TJ
    Ann Pharmacother; 2010 Jan; 44(1):43-9. PubMed ID: 20028955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres.
    Perrinet M; Décaudin B; Champs BB; Heran I; Urbina MA; Lemaitre V; Azar R; Odou P
    J Clin Pharm Ther; 2010 Aug; 35(4):395-400. PubMed ID: 20831542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A vitamin E-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial.
    Panichi V; Rosati A; Paoletti S; Ferrandello P; Migliori M; Beati S; Bernabini G; Daini R; Casani A; Angelini D; Parrini M; Rossi A; Petrone I; Barsotti G; Donadio C; Donati G; Grazi G; Manca Rizza G; Garosi G; Sansoni E; Braccagni B; Sidoti A; Boracelli D; Biagioli M; Moriconi L; Finato V; Mannarino A; Grimaldi C; Pansa F; Imperiali P; Mura C; Bianchi S; Bigazzi R
    Blood Purif; 2011; 32(1):7-14. PubMed ID: 21242686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of metabolic syndrome in patients undergoing total joint arthroplasty and relevance of biomarkers.
    Saluk J; Banos A; Hopkinson W; Rees H; Syed D; Hoppensteadt D; Abro S; Iqbal O; Fareed J
    Int Angiol; 2017 Apr; 36(2):136-144. PubMed ID: 26871396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients.
    Ogawa T; Nitta K
    Contrib Nephrol; 2015; 185():76-86. PubMed ID: 26023017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.
    Majoni SW; Ellis JA; Hall H; Abeyaratne A; Lawton PD
    Hemodial Int; 2014 Oct; 18(4):740-50. PubMed ID: 24766376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data.
    Rodby RA; Umanath K; Niecestro R; Bond TC; Sika M; Lewis J; Dwyer JP;
    Drugs R D; 2015 Sep; 15(3):271-9. PubMed ID: 26239948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a More Permeable Dialysis Membrane on ESA Resistance in Hemodialysis Patients--A Pilot Investigation.
    Teatini U; Liebchen A; Nilsson LG; Beck W; Longhena GR
    Blood Purif; 2016; 41(1-3):80-6. PubMed ID: 26536083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.